Showing 3561-3570 of 7549 results for "".
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- ICYMI: Dispatches from The Skin of Color Society’s 18th Annual Scientific Symposiumhttps://practicaldermatology.com/news/icymi-dispatches-from-the-skin-of-color-societys-18th-annual-scientific-symposium/2461157/The Skin of Color Society’s 18th Annual Scientific Symposium wowed the crowd during the American Academ
- Country Music Artist Ashley Barron Named National Scleroderma Foundation’s Celebrity Ambassadorhttps://practicaldermatology.com/news/country-music-artist-ashley-barron-named-national-scleroderma-foundations-celebrity-ambassador/2461155/Country music artist Ashley Barron is the National Scleroderma Foundation’s official Celebrity Ambassador. Barron was diagnosed with scleroderma at age five. At that time, her family had never heard of the disease. Now as Celebrity Ambassador, Barron is working to represent
- Lilly's Lebrikizumab Combined with Topical Corticosteroids Produces Significant Improvements in AD Disease Severityhttps://practicaldermatology.com/news/lillys-lebrikizumab-combined-with-topical-corticosteroids-produces-significant-improvements-in-ad-disease-severity/2461154/Atopic dermatitis patients taking lebrikizumab plus topical steroids showed significant improvements in disease severity, according to study results from the ADhere trial presented at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. At 16 weeks, 70 percent of
- Arcutis Completes Enrollment in Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-phase-3-trial-of-topical-roflumilast-foam-in-scalp-and-body-psoriasis/2461153/Enrollment in Arcutis’ ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis is complete, the company reported. Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (
- PatientFi Expands Co-marketing Agreement with Allerganhttps://practicaldermatology.com/news/patientfi-expands-co-marketing-agreement-with-allergan/2461148/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Alma Launches Alma TED, CBD+ Professional Linehttps://practicaldermatology.com/news/alma-launches-alma-ted-cbd-professional-line/2461132/Alma TED, an Ultrasound-based system with a propriety Tip engineered with Impact Delivery™, offers a non-invasive, non-traumatic option to address the market's growing hair loss concerns. Alma launched the device, along with the CBD+ Professional S
- Timber's Topical Isotretinoin Shows Benefit Across CI Subtypeshttps://practicaldermatology.com/news/timbers-topical-isotretinoin-shows-benefit-across-ci-subtypes/2461131/TMB-001, a topical isotretinoin formulated using Timber Pharmaceuticals’ patented IPEG™ delivery system, shows benefit in the treatment of congenital ichthyosis (CI), regardless of the subtype. Findings are being presented in a late-breaking presentation of a sub-analysis of the Phase
- Compulink Partners with Promptly for New Suite of Serviceshttps://practicaldermatology.com/news/compulink-partners-with-promptly-for-new-suite-of-services/2461127/Compulink Healthcare Solutions has partnered with Promptly to launch Advantage Patient Experience™, a suite of easy-to-use features intended to provide patients with the latest in mobile device convenience, while simultaneously reducing the administrative burden on office staff.